|
Vioxx News Alerts
Forbes: June 29, 2007 - Key Vioxx 18-month Usage Claim Withdrawn by
Jounal, Dealing Significant Potential Blow To Merck
Reuters, April 5, 2006 - Merck Loses Second Vioxx Case; Jury awards $4.5
million in Vioxx verdict against Merck
First Vioxx Trial Verdict and Cases Challenge 18-Month Damage Claim
First Vioxx Trial Verdict and Cases Challenge 18-Month Damage Claim
On August 19, 2005, a jury in Angleton, Texas awarded $253.4 million in damages in the case of Ernst vs. Merck & Co. The final award,
however, will not exceed $26.1 million due to Texas caps on punitive damages.
Analysts Predict Merck’s Vioxx Liabilities Could Hit $50 Billion
After Merck & Co. was assessed a $253+ million verdict in the first Vioxx trial in August 2005, financial analysts began adjusting their estimates on the size of future jury awards or settlements. With the end of the landmark trial,
analysts’ estimates have escalated to as high as $50 billion.
» Merck may settle some Vioxx cases, NJ trial looms
August 26, 2005 - Reuters - Merck & Co Inc. on Friday signaled it may
consider settling some lawsuits alleging harm from its Vioxx pain drug,
as it gears up for its second Vioxx court battle -- this time in its own
backyard.
» Merck Found Liable For Man's Death In Vioxx Trial
August 19, 2005 - Bloomberg - Merck & Co. must pay more than $253
million to the family of a Texas man who died after taking the company's
Vioxx painkiller.
» Updates from the First Vioxx Trial
August 15, 2005, Consultwebs.com, Merck Experts dispute Vioxx Death
Claims. Trial may wrap up next week.
» Updates on the progress of the first Vioxx Trial
August 5, 2005, Consultwebs.com, Expert and witness testimony weakens
Merck's position.
» Add The Feds to Those Questioning Vioxx
November 9, 2004,
Forbes.com, NEW YORK - Add the U.S. Justice Department and the
Securities and Exchange Commission to the club circling Merck and
Vioxx. Yesterday, Merck, in an otherwise routine quarterly filing,
revealed that federal investigators were investigating what Merck knew
in advance of its recent withdrawal of its popular painkiller on the
grounds that it boosted the risk of heart attacks in long-term users.
» Wall Street Study Projects 50,000+ Lawsuits
Estimate assumes
jury awards or settlements would require Merck to pay
anywhere from $100,000 to $300,000 for each lawsuit, and
that Merck might also pay another $1 billion to $2
billion in suits by Vioxx users who claim some other
harm.
» Merck falls as e-mails suggest Vioxx smoking gun
NEW YORK, Nov 1 (Reuters) - Merck & Co. Inc.'s <MRK.N>
Vioxx recall is mushrooming into a product-liability
nightmare that erased another $23 billion of the
company's valuation on Monday, but analysts said it will
likely withstand the crisis. Merck may eventually pay
$5 to $15 billion payout.
» Merck Shares Plunge on Vioxx Denial News
November 1, 2004,
Forbes.com, Shares of Merck & Co. plunged more than 7
percent Monday after a media report said that documents
show the pharmaceutical giant hid or denied evidence for
years that its blockbuster arthritis drug Vioxx cause
heart problems.
» Recall Rattles Patients ; Vioxx Heart Risk Should
Vanish By Discontinuing Use of Drug, Physician Says.
October 19, 2004, RedNova.com, Some arthritis
sufferers who appreciated the anti-inflammatory medicine
Vioxx for its power over pain are now worried that the
medicine might have hurt their heart. Dr. Brent Mohr, a
rheumatologist at the South Bend Clinic, said it will
take a while for him and his staff to help patients make
the transition to a different pain reliever.
» Vioxx was long under research microscope
October 12, 2004,
Newsday.com, The study's findings were dramatic: 20
patients on Vioxx had heart attacks. Only four had heart
attacks on the comparison drug. But that's not the study
that prompted Merck & Co. to yank Vioxx off the market
two weeks ago.....
» Merck Braces For Wave of Vioxx Lawsuits
Sat, Oct. 02, 2004,
Philadelphia Inquirer (Philly.com) -- "Our preliminary
.....
» How did Vioxx debacle happen?
10/12/2004 USA Today -- Merck yanked Vioxx on
Sept. 30 because a new study had found a higher rate of
heart attacks and strokes in patients taking the drug
than in those on a placebo...
» Merck Braces For Wave of Vioxx Lawsuits
Sat, Oct. 02, 2004, Philadelphia Inquirer (Philly.com)
-- "Our preliminary estimate is that about 16,632 people
may ultimately file a legitimate lawsuit" against Merck
over Vioxx, analyst Tim Anderson wrote in a report
issued yesterday by the Prudential Equity Group...
» CNN: Arthritis drug Vioxx being pulled
NEW YORK (Reuters) -- The arthritis drug Vioxx, used
by millions of people around the world, is being pulled
off the market after a study confirmed long-standing
concerns that it raises the risk of heart attack and
stroke, the manufacturer, Merck & Co., said today...
» Dow Average Falls After Merck Withdraws Vioxx;
Nasdaq Advances
Sept. 30 (Bloomberg) -- The Dow Jones Industrial Average
dropped after Merck & Co. retracted its third-quarter
profit forecast because the company said it will no
longer sell the Vioxx painkiller that generated $2.5
billion in sales last year.
» ABC News: "A Disaster": Merck Recalls Arthritis
Drug Vioxx
Merck Recalls Vioxx Because Data From Clinical Trial
Finds Higher Risk of Heart Attack, Stroke
» Dow Average Falls as Merck Pulls Vioxx
Sept. 30 (Bloomberg) -- The Dow Jones Industrial Average dropped after
Merck & Co. withdrew the Vioxx painkiller and reduced its 2004 profit
forecast. The decision will lead to ``a big hit to earnings and a big
hit for the growth of Merck,'' said Charles Bath, who owns Merck shares
and helps manage $375 million at Diamond Hill Investment Group in
Columbus, Ohio.
» Pfizer Acting to Fill Vioxx Void
Oct.1, 2004 - Drug giant Pfizer Inc. said Friday it is actively taking
steps to fill the vacuum created by rival Merck & Co.'s Thursday
withdrawal of competing drug Vioxx off the market because of studies
showing a heart attack risk. Pfizer said it is approaching wholesalers,
pharmacy chains, pharmacy benefit managers and other managed care
organizations to assure them that the company will meet potential
patient needs with its arthritis drug Celebrex.
» Expert: Vioxx Risk Could Have Been Spotted Sooner
Morning Edition, October 1, 2004 · A voluntary withdrawal of Vioxx from
the market is the latest in a string of safety issues for the drug
market. Dr. Alistair Wood, of the Vanderbilt School of Medicine, says
the serious dangers Vioxx posed could have been found before millions
began taking the drug.
» Merck options' spike before Vioxx news questioned
CHICAGO, Sept 30 (Reuters) - Heavy buying of bearish options on Merck &
Co. (MRK.N: Quote, Profile, Research) a day before it pulled its key
arthritis drug Vioxx off the market is raising eyebrows among options
market players. Some traders appear to have scored big on the bombshell
news, which wiped out $27 billion of Merck's market value.
» Alternatives exist for users of Vioxx
Oct.1, 2004 - Patients who take Vioxx for chronic pain should stop using
it immediately and call their doctor to seek alternative treatments,
medical professionals said. Bob Lautman, owner of Mill Pharmacy and
Surgical in Mount Laurel, said he received a few calls Thursday from
customers concerned about Vioxx.
» Vioxx Recall Worries Local Patients, Doctors Give Advice
Sept.30, 2004 - Doctors' offices in Tyler have been busy all day taking
calls from patients wondering what to do about their Vioxx. Dr. Steven
Cohen of Trinity Clinic says he's angry at the drug maker. He says Merck
should have notified physicians before making the sudden announcement to
the public and causing all the concern.
»
Merck recalls Vioxx, shares plunge
Merck & Co. is pulling its widely used arthritis drug, Vioxx, from the
market after five years, confirming that the drug presents
cardiovascular risks. Shares of the Whitehouse Station, N.J.-based firm
plunged as much as 28% to an eight-year low of $32.46 in morning
trading. They closed down 26.85, at $33.00.
» Merck's Vioxx Gets OK for Child Arthritis
Sept.8, 2004 - Merck (MRK:NYSE - news - research) said Wednesday that
the Food and Drug Administration has approved its arthritis drug Vioxx
for treating juvenile rheumatoid arthritis. The FDA's decision allows
Merck to market the drug directly to physicians treating this disease,
which is the most common form of arthritis in children, affecting an
estimated 30,000 to 50,000 in the U.S.
» FDA Nod Won't Guarantee Drug Safety
FRIDAY, Sept. 3 (HealthDayNews) -- A 60-year-old woman with degenerative
disk disease recently came into Dr. Allen Lebovits' Manhattan office
with a complaint. This time, the grievance wasn't about the pain but
about news reports linking Vioxx, her pain reliever, with an increased
risk of heart attacks and sudden cardiac deaths.
» Study links high doses of arthritis meds to increased heart attack
risk
Aug.20, 2004 - Taking more than 25 mg per day of rofecoxib (Vioxx) is
linked to a tripling of the risk of heart attack, said a paper presented
in August at the International Society for Pharmacoepidemiology
Conference in Bordeaux, France. Researchers analyzed data from the HMO
Kaiser Permanente for all patients prescribed COX-2 inhibitors or
non-steroidal anti-inflammatories.
Back to top
Copyright - US Vioxx Lawyers - Brown & Crouppen
- St. Louis, Missouri
Vioxx Lawyers, Celebrex, Dangerous Drug Litigators,
Pharmaceutical Negligence, Arthritis Drug Attorneys,
Unsafe Drugs, Osteoarthritis, Cox-2 Inhibitors, Heart
Attack, Stroke, Kidney Problems, Vioxx News Alert,
Recall
Site by
Consultwebs.com,
Inc. - Webs for
Lawyers | Law Firms, News by
LegalNewsFeeds.com. |
|
